Marshall Wace
TGTX icon

Marshall Wace’s TG Therapeutics TGTX Stock Holding History

Marshall Wace’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$854K Buy
+25,693
New +$766K ﹤0.01% 2208
2024
Q3 		– Sell
-2,051,762
Closed -$36.5M – 2950
2024
Q2 		$36.5M Buy
+2,051,762
New +$32.7M 0.05% 330
2024
Q1 		– Sell
-1,020,102
Closed -$17.4M – 2798
2023
Q4 		$17.4M Buy
+1,020,102
New +$11.9M 0.03% 514
2020
Q2 		– Sell
-24,637
Closed -$242K – 1935
2020
Q1 		$242K Buy
+24,637
New +$311K ﹤0.01% 1146

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Marshall Wace's TGTX Position: Q1 2026 in Review

Marshall Wace opened a new position in TG Therapeutics (TGTX) in Q1 2026: 25,693 shares worth $854K. The stake represents ﹤0.01% of the portfolio and ranks #2208 among its holdings. This is a return to the name: Marshall Wace previously reported a position in TGTX as recently as Q2 2024.

Marshall Wace first reported a position in TGTX in Q1 2020 and has held it in 4 quarters since. The position peaked at $36.5M in Q2 2024. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Marshall Wace held 25,693 shares of TG Therapeutics worth $854K as of Q1 2026.
  • TG Therapeutics was a new Marshall Wace position in Q1 2026.
  • TG Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2208 holding.
  • Marshall Wace first reported a position in TG Therapeutics in Q1 2020 and has held it in 4 quarters since.
  • Marshall Wace's TG Therapeutics position peaked at $36.5M in Q2 2024.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.